SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense community speculation as investors position themselves ahead of the upcoming earnings report, fueling a heated standoff between those betting on a short squeeze and those skeptical of the company's valuation. Market participants are fixated on high short interest and potential revenue growth driven by defense sector contracts, leading to significant volatility as traders debate whether the stock will continue its upward momentum or face a correction.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing high volatility as investors react to a significant revenue miss and weaker-than-expected margins, fueling intense debate over the company's valuation relative to its growth. The community is actively discussing the stock's massive price swings, concerns regarding upcoming share lockup expirations, and conflicting perspectives on whether the company represents a legitimate AI powerhouse or an overvalued asset.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a negative opinion from the EMA's CHMP regarding the marketing authorization for YARTEMLEA in Europe. Despite this regulatory hurdle, the community remains focused on the U.S. launch momentum, with discussions highlighting upcoming catalysts like the effective date for the J-code and the anticipated approval of the New Technology Add-On Payment.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense bearish pressure following a negative analyst downgrade that highlighted significant revenue headwinds from its China marketplace reset. While the stock's multi-year downtrend has deeply polarized the community, many investors are debating whether the current price represents a capitulation bottom or a persistent value trap given ongoing competition and market sentiment.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is trending as investors react to strong quarterly earnings, where double-beat results and aggressive growth guidance fueled bullish sentiment regarding the AI optical supercycle. While some traders discuss profit-taking and volatility in overnight trading, the community remains focused on the company's expanding capacity and the broader transition from copper to fiber-optic infrastructure.

Investment Managers Series Trust II - Tradr 2X Short NBIS Daily ETF

Tradr 2X Short NBIS Daily ETF

The NBIZ leveraged ETF is experiencing intense volatility and community debate as traders grapple with significant price decay following its inverse tracking of Nebius. Investors are actively discussing the risks of holding the instrument through earnings and high-beta market swings, often highlighting the technical challenges of managing a 2X daily inverse product against a volatile underlying AI stock.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is trending as investors weigh strong AI networking demand and record product orders against cautious sentiment surrounding headcount reductions and competitive pressures. The community remains divided, with many highlighting the stock as an undervalued AI infrastructure play poised for future growth, while others express skepticism regarding its ability to maintain margins and market share against rapidly evolving tech peers.

Cheesecake Factory, Inc. engages in the operation of restaurant chains. It operates through the following segments: The Cheesecake Factory Restaurants, North Italia, Other FRC, and Other. The Cheesecake Factory Restaurants segment offers appetizers, pizza, seafood, steaks, chicken, burgers, small plates, pastas, salads, sandwiches and omelettes, and a selection of gluten-free items. The North Italia segment specializes in Italian cuisine. The Other FRC segment includes brands acquired from Fox Restaurant Concepts. The Other segment consists of the Flower Child brand, along with other businesses. The company was founded by David M. Overton, Oscar Overton, and Evelyn Overton in 1972 and is headquartered in Calabasas Hills, CA.

Cheesecake Factory Inc. (The)

Cheesecake Factory Inc.

Cheesecake Factory is trending as bullish investors drive the stock to new highs, fueled by its aggressive multi-brand expansion strategy and strong operational execution despite broader restaurant sector headwinds. While some community members celebrate the consistent gains and potential for a squeeze, others are expressing skepticism over the stock's valuation and high RSI levels, noting significant insider selling as a point of contention.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing high community engagement driven by strong quarterly revenue growth and increased revenue guidance, alongside active speculation regarding upcoming government contracts and partnerships. Investors are closely monitoring the company's progress in quantum hardware milestones while debating the impact of ongoing research costs on short-term price volatility.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors digest the company's transformation into an AI infrastructure powerhouse, with heavy community focus on the massive short interest and potential for a squeeze. Bulls are citing the record quarterly revenue and the strategic acquisition of Northern Data's GPU and data center assets as catalysts for a long-term valuation re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annualized basis producing an average annual return of 11.31%. Currently, Gilead Sciences has a market capitalization ofread more...

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.

PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against iTonic Holdings Ltd. (ITOC)- Previously Knowns as Pheton Holdings Ltd. (PTHL)

PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against iTonic Holdings Ltd. (ITOC)- Previously Knowns as Pheton Holdings Ltd. (PTHL) PTHL Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against...

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +4.53% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026. Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting...

Shareholder Alert: Robbins LLP Informs Shareholders of the iTonic Holdings Ltd. (ITOC) Previously Known as Pheton Holdings Ltd. (PTHL) Class Action Lawsuit

Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Pheton Holdings Ltd (NASDAQ: PTHL) (n/k/a iTonic Holdings Ltd. (NASDAQ: ITOC)) securities between September 5, 2024 and July 29, 2025 (the "Class...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026

Equity

Bearish Sentiment

Track GILD stock price, charts, news and real-time market activity on Stocktwits. Join the GILD message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Gilead Sciences, Inc stock.

GILD Stock Price Today - Gilead Sciences, Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$135.87
Prev Close	$135.77
Open	$133.99
Dividend Yield	2.57%
50-Day Moving Average	$129.78
Beta	0.36
Avg. Volume	6.66M
PE Ratio	-51.15

52-Week High	$157.29
52-Week Low	$108.46
Market Capitalization	$168.35B
EPS (Annual)	$6.78
Price to Book	14.25
Revenue Per Employee	$1.73M

Feed

News

Sentiment

Earnings

Fundamentals

Info